The theme for this year’s Cardinal Health RBC 2014 is “Leading Change.” For community pharmacists, that means playing a more active role in patient care. And Cardinal Health has a suite of services to help community pharmacists take the next step in making a difference in their patients’ lives — the Cardinal Health Adherence Suite.
Actavis confirmed that the U.S. District Court for the District of Delaware found certain claims of U.S. Patent Nos. 6,335,031 and 6,316,023 valid and infringed by the company's rivastigmine transdermal system, a generic version of Exelon Patch from Novartis.
A series of new clinical studies released Tuesday found that Cardinal Health Specialty Solutions’ Clinical Pathways program reduces the cost of cancer treatment, improves clinical care and shows promise for guiding treatment of other high-cost, complex diseases beyond cancer.
Actavis has reached an agreement with Janssen Pharmaceuticals to continue supplying the authorized generic version of Janssen's Concerta (methylphenidate hydrochloride extended-release tablets), the company announced.
Actavis on Tuesday announced that it has received final approval from the Food and Drug Administration on its abbreviated new drug application for a generic version of Mallinckrodt's Exalgo (hydromorphone hydrochloride extended-release tablets 8 mg, 12 mg and 16 mg).
Actavis on Wednesday announced the proposed senior management team that will lead the specialty pharmaceutical company pending the successful close of the acquisition of Forest Labs, which is anticipated at mid-year.
Perrigo on Monday announced that it received approval from the Food and Drug Administration for azelastine hydrochloride nasal spray (0.15%), a generic version of Astepro. The drug is indicated for people ages 12 years and older and is used to treat nasal symptoms brought on by seasonal allergies or environmental irritants.
Actavis on Monday announced that it has entered into an agreement with Valeant Pharmaceuticals International to settle all outstanding patent litigation related to Actavis' generic version of Acanya (clindamycin phosphate and benzoyl peroxide) Gel, 1.2%/2.5%.
Cardinal Health on Monday announced that its board of directors elected David J. Anderson as an independent director. Anderson most recently served as SVP and CFO of Honeywell International. He also will serve on the board's audit committee.
Actavis and Forest Laboratories on Thursday announced that they have each received a request for additional information from the Federal Trade Commission in connection with Actavis' pending acquisition of Forest.
Among severely obese people, vitamin D may make the difference between an active and a more sedentary lifestyle, according to a new study published in the Endocrine Society’s Journal of Clinical Endocrinology & Metabolism on Tuesday.
Actavis on Tuesday announced that it has entered into an agreement with Mylan and Famy Care to settle all outstanding patent litigation related to Mylan's generic version of Generess FE (norethindrone, ethinyl estradiol and ferrous fumarate chewable tablets).
Mallinckrodt and Questcor Pharmaceuticals on Monday announced that they have entered into a definitive merger agreement under which Mallinckrodt will acquire Questcor in a transaction valued at approximately $5.6 billion.